News|Articles|April 29, 2011
REMS Challenges Discussed
Advertisement
In late April, the Center for Business Intelligence (CBI) held a two-day forum on Drug Safety. The focus was REMS, the FDAs enforceable Risk Evaluation and Mitigation Strategy, and included discussions on REMS assessment, challenges, case studies, technology and more.
Applied Clinical Trials Editor Lisa Henderson attended the conference and blogged live. You can read the blogs by clicking the links below.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
4
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
5